SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: billkirn who wrote (562)4/6/1997 8:12:00 PM
From: Brad C. Dunlap   of 1762
 
I was one of those stockholders that did sell agouron the day of approval, but could have saved myself about 12 pts if I hadn't hesitated. Sure if Idec were to run to 50 in anticipation of FDA approval which would be a comparable mkt cap to Agouron when it was at 100, I would be strongly tempted to sell into the news. If you could try to feel them out as to what data are they going to be presenting at the upcoming ASCO conference at the end of May. I doubt if the YB28 data will be available but try to read between the lines as to how that study is progressing. The company line is that they will have the data by the fall. You also might want to ask about the small molecule products that Idec recently acquired and when we could expect to see the phase II data from these products.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News